Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MEDI 9253

Next Previous
X
Search
Drug Profile

MEDI 9253

Alternative Names: MEDI9253; Recombinant Newcastle disease virus encoding interleukin-12

Latest Information Update: 28 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; Interleukin-12 expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 31 May 2024 AstraZeneca completes a phase I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in France and USA (IV) (NCT04613492)
  • 06 Mar 2023 Efficacy, adverse events and Pharmacokinetics data from a phase I trial in Solid tumours presented at the 21st International Congress on Targeted Anticancer Therapies (TAT-2023)
  • 28 Feb 2023 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA, France (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top